{"denoms":[{"counts":[{"groupId":"BG000","value":"17"}],"units":"Participants"}],"groups":[{"description":"SyB L-0501: The administration of SyB L-0501 at 90 mg/m\\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.","id":"BG000","title":"SyB L-0501"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.8","value":"63.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"20-29 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"30-39 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"40-49 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"50-59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"60-69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"70-79 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Immunoglobulin G"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Immunoglobulin A"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Immunoglobulin D"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Bence Jones type"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"κ"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"λ"}],"description":"One participant could carry multiple subtypes of myeloma.","paramType":"NUMBER","title":"Subtype of myeloma","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Absent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Present"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Proteasome inhibitor"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"IMIDs"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Alkylating agent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Prior therapy","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"2"}],"description":"The criteria of Eastern Cooperative Oncology Group (ECOG) performance status are shown below.\n\n0: Fully active, able to carry on all pre-disease performance without restriction , 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work , 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours","paramType":"NUMBER","title":"Performance status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"III"}],"description":"The criteria of clinical disease stage (International Staging System) are shown below.\n\nstage I: Serum β2-microglobulin \\< 3.5 mg/L plus serum albumin ≥ 3.5 g/dL, stage II: neither stage I nor III , stage III: Serum β2-microglobulin ≥ 5.5 mg/L","paramType":"NUMBER","title":"Clinical disease stage (International Staging System)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Absent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Present"}],"paramType":"NUMBER","title":"Medical history","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Absent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"Present"}],"paramType":"NUMBER","title":"Accompanying symptoms of the primary disease","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Absent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Present"}],"description":"A complication is a disease or condition that arises as a result of multiple myeloma.","paramType":"NUMBER","title":"Complication","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1.59","value":"4.03"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Serum β2 microglobulin","unitOfMeasure":"mg/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.95","value":"159.05"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Height","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.06","value":"56.86"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body weight","unitOfMeasure":"kg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.181","value":"1.576"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body surface area","unitOfMeasure":"m^2"}]}